Kristina Navrazhina1, John W Frew2, Patricia Gilleaudeau2, Mary Sullivan-Whalen2, Sandra Garcet2, James G Krueger3. 1. Laboratory of Investigative Dermatology, The Rockefeller University, New York, NY; Weill Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD-PhD Program, New York, NY. 2. Laboratory of Investigative Dermatology, The Rockefeller University, New York, NY. 3. Laboratory of Investigative Dermatology, The Rockefeller University, New York, NY. Electronic address: jgk@rockefeller.edu.
Abstract
BACKGROUND: Hidradenitis suppurativa (HS), also known as acne inversa, is a chronic, painful, and burdensome inflammatory disease manifesting in nodules and abscesses, with progression to chronically draining tunnels in later-stage disease. OBJECTIVE: We sought to determine whether HS tunnels are immunologically active participants in disease activity. METHODS: Skin biopsy specimens were obtained by using ultrasound guidance in untreated patients with HS and those enrolled in an open-label study of brodalumab (ClinicalTrials.gov identifier NCT03960268) for patients with moderate-to-severe HS. RESULTS: Immunohistochemistry of HS biopsy specimens demonstrated that the epithelialized HS tunnels recapitulate the psoriasiform epidermal hyperplasia morphology of the overlying epidermis, displaying molecular inflammation, including S100A7 (psoriasin) positivity, as well as features of epidermal skin, including loricrin, filaggrin, lipocalin-2, and Melan-A positive cells. Tunnels were associated with increased infiltration of T cells, dendritic cells, and neutrophils; formation of neutrophil extracellular traps, and increased expression of psoriasiform proinflammatory cytokines. Unsupervised hierarchical clustering demonstrated a separation of HS samples based on the presence or absence of tunnels. Tunnels isolated by microdissection had higher levels of epithelium-derived inflammatory cytokines compared with the overlying epidermis and healthy controls. Clinically, the size and draining of the tunnels were decreased with treatment with the IL-17RA antagonist brodalumab. CONCLUSION: These data suggest that tunnels are a source of inflammation in HS.
BACKGROUND: Hidradenitis suppurativa (HS), also known as acne inversa, is a chronic, painful, and burdensome inflammatory disease manifesting in nodules and abscesses, with progression to chronically draining tunnels in later-stage disease. OBJECTIVE: We sought to determine whether HS tunnels are immunologically active participants in disease activity. METHODS: Skin biopsy specimens were obtained by using ultrasound guidance in untreated patients with HS and those enrolled in an open-label study of brodalumab (ClinicalTrials.gov identifier NCT03960268) for patients with moderate-to-severe HS. RESULTS: Immunohistochemistry of HS biopsy specimens demonstrated that the epithelialized HS tunnels recapitulate the psoriasiform epidermal hyperplasia morphology of the overlying epidermis, displaying molecular inflammation, including S100A7 (psoriasin) positivity, as well as features of epidermal skin, including loricrin, filaggrin, lipocalin-2, and Melan-A positive cells. Tunnels were associated with increased infiltration of T cells, dendritic cells, and neutrophils; formation of neutrophil extracellular traps, and increased expression of psoriasiform proinflammatory cytokines. Unsupervised hierarchical clustering demonstrated a separation of HS samples based on the presence or absence of tunnels. Tunnels isolated by microdissection had higher levels of epithelium-derived inflammatory cytokines compared with the overlying epidermis and healthy controls. Clinically, the size and draining of the tunnels were decreased with treatment with the IL-17RA antagonist brodalumab. CONCLUSION: These data suggest that tunnels are a source of inflammation in HS.
Authors: A Jenei; Z Dajnoki; B Medgyesi; K Gáspár; G Béke; Á Kinyó; G Méhes; Z Hendrik; T Dinya; D Törőcsik; C C Zouboulis; E P Prens; T Bíró; A Szegedi; A Kapitány Journal: J Invest Dermatol Date: 2018-10-31 Impact factor: 8.551
Authors: James G Krueger; Keith A Wharton; Thomas Schlitt; Maria Suprun; Rebecca I Torene; Xiaoyu Jiang; Claire Q Wang; Judilyn Fuentes-Duculan; Nicole Hartmann; Thomas Peters; Irina Koroleva; Rainer Hillenbrand; Martin Letzkus; Xiaojing Yu; Yue Li; Anton Glueck; Anke Hasselberg; Brian Flannery; Mayte Suárez-Fariñas; Wolfgang Hueber Journal: J Allergy Clin Immunol Date: 2019-05-24 Impact factor: 10.793
Authors: K Wolk; J Wenzel; A Tsaousi; E Witte-Händel; N Babel; C Zelenak; H-D Volk; W Sterry; S Schneider-Burrus; R Sabat Journal: Br J Dermatol Date: 2017-09-19 Impact factor: 9.302
Authors: C C Zouboulis; N Desai; L Emtestam; R E Hunger; D Ioannides; I Juhász; J Lapins; L Matusiak; E P Prens; J Revuz; S Schneider-Burrus; J C Szepietowski; H H van der Zee; G B E Jemec Journal: J Eur Acad Dermatol Venereol Date: 2015-01-30 Impact factor: 6.166
Authors: Alexa B Kimball; Martin M Okun; David A Williams; Alice B Gottlieb; Kim A Papp; Christos C Zouboulis; April W Armstrong; Francisco Kerdel; Michael H Gold; Seth B Forman; Neil J Korman; Evangelos J Giamarellos-Bourboulis; Jeffrey J Crowley; Charles Lynde; Ziad Reguiai; Errol-Prospero Prens; Eihab Alwawi; Nael M Mostafa; Brett Pinsky; Murali Sundaram; Yihua Gu; Dawn M Carlson; Gregor B E Jemec Journal: N Engl J Med Date: 2016-08-04 Impact factor: 91.245
Authors: Kristina Navrazhina; John W Frew; David Grand; Samuel C Williams; Hong Hur; Juana Gonzalez; Sandra Garcet; James G Krueger Journal: Br J Dermatol Date: 2022-06-02 Impact factor: 11.113
Authors: Mahendra Pratap Kashyap; Jasim Khan; Rajesh Sinha; Lin Jin; Venkatram Atigadda; Jessy S Deshane; Ayesha R Ahmed; Ali Kilic; Chander Raman; M Shahid Mukhtar; Craig A Elmets; Mohammad Athar Journal: Semin Cell Dev Biol Date: 2022-02-04 Impact factor: 7.499
Authors: Samuel Der Sarkissian; Schapoor Hessam; Joslyn S Kirby; Michelle A Lowes; Dillon Mintoff; Haley B Naik; Hans Christian Ring; Nisha Suyien Chandran; John W Frew Journal: JAMA Dermatol Date: 2022-03-01 Impact factor: 11.816
Authors: Sadaf Mohammadi; Abbas Gholami; Lina Hejrati; Masoomeh Rohani; Raheleh Rafiei-Sefiddashti; Alireza Hejrati Journal: J Family Med Prim Care Date: 2021-11-29
Authors: Gautham Vellaichamy; Anya T Amin; Peter Dimitrion; Zaakir Hamzavi; Li Zhou; Indra Adrianto; Qing-Sheng Mi Journal: Front Genet Date: 2022-08-26 Impact factor: 4.772
Authors: Kristina Navrazhina; Sandra Garcet; John W Frew; Xiuzhong Zheng; Israel Coats; Emma Guttman-Yassky; James G Krueger Journal: J Am Acad Dermatol Date: 2021-07-30 Impact factor: 11.527
Authors: Z Dajnoki; O Somogyi; B Medgyesi; A Jenei; L Szabó; K Gáspár; Z Hendrik; P Gergely; D Imre; S Póliska; D Törőcsik; C C Zouboulis; E P Prens; A Kapitány; A Szegedi Journal: J Eur Acad Dermatol Venereol Date: 2021-11-26 Impact factor: 9.228